Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-12-17

Clinical Trial Update: Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin [Phase 2]

View source ↗

Summary

Phase 2 trial of antineoplaston therapy in unknown primary carcinoma was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Antineoplaston therapy

Snippet

Sponsor: Burzynski Research Institute | Conditions: Unknown Primary Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2020-12-17